/
Note: A glossary of terms used in this Form 10-K appears at the end of this Item 1. Overview We are a diagnostics company with proprietary molecular and bioinformatics technology that we are applying to change disease management worldwide.
The business is unprofitable at the operating level (-13.44% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 35.9%, still solid.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$2.50B
▲ +35.9% YoY
Net Income (TTM)
-$226M
▼ -9.3% YoY
Op. Margin
-12.97%
▼ -0.3pp YoY
ROIC
-14.99%
▼ -1.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$105M
▲ +57.6% YoY
Op. Cash Flow (TTM)
$211M
▲ +58.7% YoY
Net Debt
-$848M
Net Cash Position
Cash & Equiv.
$1.09B
5Y CAGR: +42.6%
Continue Research